Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07390240 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia

Study acronym: ATLANTIS
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 years later Jun 30, 2027 → Jun 30, 2030
Primary endpoints removed 61 → 55 primary endpoints
See other at-risk trials from AstraZeneca

Record History

  1. Primary and study completion pushed from Jun 30, 2027 to Jun 30, 2030 Primary endpoint(s) modified · Eligibility criteria expanded, about 561 words Show 2 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 561 words
  2. 3 versions Re-verified since May 14, 2026, no change to tracked fieldsv4-v6
  3. Study sites: 2 to 4v3
  4. Site details revised at 1 of 2 sitesv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
The effect of monoallelic variants in the ALPL gene on the natural course of hypophosphatasia (HPP) in children and adults in Russia (ATLANTIS)
Trial Details
NCT Number NCT07390240
Lead Sponsor AstraZeneca
Conditions Hypophosphatasia
Enrollment 55 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov